Official Title
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Brief Summary

The purpose of this study is to continue to provide olaratumab to eligible patients whoare currently receiving olaratumab commercially for the treatment of soft tissue sarcoma(STS).

Available
Individual Patients
Soft Tissue Sarcoma

Drug: Olaratumab

Administered intravenously (IV)
Other Name: LY3012207

Eligibility Criteria

Inclusion Criteria:

- Are currently receiving olaratumab and who, in consultation with their treating
physician, want to continue their course of therapy.

- Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to
curative treatment with surgery or radiotherapy.

- Have given written informed consent.

- Have an absolute neutrophil count (ANC) ≥1,000/microliter.

- Females of childbearing potential and males must agree to use highly effective
contraceptive precautions during treatment with olaratumab and up to 3 months
following the last dose of olaratumab. A highly effective method of birth control is
defined as one that results in a low failure rate (that is, <1% per year) when used
consistently and correctly, such as implants, injectables, combined oral
contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence,
or a vasectomized partner.

Exclusion Criteria:

- Breastfeeding (patients who discontinue breastfeeding would be considered eligible).

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Austria
Brazil
Canada
Hungary
India
Italy
Korea, Republic of
Spain
Taiwan
United Kingdom
United States
Locations

Ironwood Cancer & Research Centers
Glendale, Arizona, United States

Marin Specialty Care, Inc
Greenbrae, California, United States

The Angeles Clinic & Research Institute
Los Angeles, California, United States

Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States

Kaiser Permanente West Los Angeles
Los Angeles, California, United States

Kaiser Permanente Moreno Valley
Moreno Valley, California, United States

University of Colorado Health Hospital
Aurora, Colorado, United States

UCHealth Cancer Center
Fort Collins, Colorado, United States

Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States

Mayo Clinic in Florida
Jacksonville, Florida, United States

Ocala Oncology, P.A.
Ocala, Florida, United States

Florida Cancer Specialists
Orlando, Florida, United States

Orlando Health UF Health Cancer Center
Orlando, Florida, United States

Florida Cancer Specialists
Sarasota, Florida, United States

Oncology-Hematology Associates of West Broward
Tamarac, Florida, United States

Northside Hospital
Athens, Georgia, United States

Tift Regional Health System Anita Stewart Oncology Center
Tifton, Georgia, United States

Beacon Cancer Care
Coeur d'Alene, Idaho, United States

Rush University Medical Center
Chicago, Illinois, United States

Illinois Cancer Care
Peoria, Illinois, United States

Hematology Oncology Clinic
Baton Rouge, Louisiana, United States

Alton Ochsner Medical Center
New Orleans, Louisiana, United States

University of Maryland, Baltimore
Baltimore, Maryland, United States

SKCCC at Johns Hopkins
Baltimore, Maryland, United States

Baltimore Washington Health Services
Glen Burnie, Maryland, United States

University of Massachusetts Medical Center
Worcester, Massachusetts, United States

Henry Ford Macomb Hospital
Clinton Township, Michigan, United States

Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States

St. Luke's Hospital of Duluth
Duluth, Minnesota, United States

Masonic Cancer Center, University
Minneapolis, Minnesota, United States

Jackson Oncology Associates, PLLC
Jackson, Mississippi, United States

University of Mississippi School of Medicine
Jackson, Mississippi, United States

County Oncologist, Inc.
Saint Louis, Missouri, United States

Cooper Hospital University Medical Center
Camden, New Jersey, United States

Regional Cancer Care Associates, LLC
East Brunswick, New Jersey, United States

Hudson Valley Cancer Center
Fishkill, New York, United States

SUNY Upstate Medical University
Syracuse, New York, United States

SUNY Upstate Medical University
Syracuse, New York, United States

East Carolina School of Medicine
Greenville, North Carolina, United States

Aultman Medical Group Hematology & Oncology
Canton, Ohio, United States

University of Cincinnati Cancer Institute
Cincinnati, Ohio, United States

Cleveland Clinic Foundation
Cleveland, Ohio, United States

The James Cancer Hospital
Columbus, Ohio, United States

UPMC Hillman Cancer Center
Greenville, Pennsylvania, United States

Steward Sharon Regional Cancer Center
Hermitage, Pennsylvania, United States

UPMC Hillman Cancer Center
New Castle, Pennsylvania, United States

Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, United States

The West Clinic
Germantown, Tennessee, United States

Tennessee Oncology PLLC
Hixson, Tennessee, United States

UVAHS Emily Couric Clin Cancer Ctr
Charlottesville, Virginia, United States

Kaiser Permanente of WA
Olympia, Washington, United States

Harrison HealthPartners Hematology
Poulsbo, Washington, United States

Seattle Integrative Cancer Center
Renton, Washington, United States

Mon Health Medical Center
Morgantown, West Virginia, United States

SSM Health Cancer Care Center
Madison, Wisconsin, United States

West Allis Memorial Hospital
West Allis, Wisconsin, United States

Ordensklinikum Linz GmbH Elisabethinen
Linz, Oberösterreich, Austria

Kepler Universitätsklinikum GmbH, Med Campus III
Linz, Oberösterreich, Austria

CLION - Clínica de Oncologia
Salvador, Bahia, Brazil

Instituto Londrina de Radioterapia
Londrina, Paraná, Brazil

CHUM
Montreal, Quebec, Canada

Allan Blair Cancer Centre
Regina, Saskatchewan, Canada

Allan Blair Cancer Centre
Regina, Saskatchewan, Canada

Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház
Nyiregyhaza, Szabolcs-Szatmár-Bereg, Hungary

National Institute of Oncology
Budapest, Hungary

Healthcare Global Enterprises Limited (HCG)
Bangalore, Karnataka, India

Istituto Oncologico Veneto IRCCS
Padova, Veneto, Italy

IRCCS - AOU di Bologna
Bologna, Italy

Ospedale Santa Chiara di Trento
Trento, Italy

Inha University Hospital
Incheon, Incheon-gwangyeoksi [Incheon], Korea, Republic of

Gachon University Gil Medical Center
Namdong-gu, Incheon, Korea, Republic of

Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, Korea, Republic of

Pusan National University Hospital
Busan, Pusan-Kwangyǒkshi, Korea, Republic of

Wonkwang University Hospital
Iksan-si, Jeonlabuk-do, Korea, Republic of

Hospital Universitario de Canarias
Tenerife, La Laguna, Spain

Hospital De Navarra
Pamplona, Navarra, Spain

Clínica Mompia
Cantabria, Santa Cruz De Bezana, Spain

Hospital Universitari Vall d'Hebron
Barcelona, Spain

Cl. Universitaria Navarra
Madrid, Spain

Centro Oncológico MD Anderson
Madrid, Spain

Hospital Clinico San Carlos
Madrid, Spain

Hospital Madrid Norte Sanchinarro
Madrid, Spain

Gerencia de Asistencia Sanitaria de Segovia_Hospital General de Segovia
Segovia, Spain

Hospital Universitario Virgen Del Rocio
Sevilla, Spain

Hospital Universitario Virgen Del Rocio
Sevilla, Spain

Fundación Instituto Valenciano de Oncología
Valencia, Spain

Hospital Universitario La Fe de Valencia
Valencia, Spain

China Medical University Hospital
Taichung, Taiwan

The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom

Ninewells Hospital
Dundee, Scotland, United Kingdom

Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom

Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom

Contacts

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
clinicaltrials.gov@lilly.com

Eli Lilly and Company
NCT Number
MeSH Terms
Sarcoma
Olaratumab